This novel compound has demonstrated comparable stability and heightened efficacy for eliminating lung cancer and prostate cancer cells, positioning it as a potent candidate for developing targeted therapy against E2F1-induced tumors (Shaik et al., 2018). The gene discussed is E2F1; the disease is lung carcinoma.